About NANTCELL, INC.
ImmunityBio is a biotechnology company focused on developing immunotherapies to treat cancer and infectious diseases by activating the patient's immune system. The company is advancing investigational therapies, including ANKTIVA®, and has a robust clinical pipeline across multiple therapeutic areas.
Development of immunotherapies that activate both innate and adaptive immune responsesResearch and clinical trials in cancer and infectious diseasesPipeline of investigational therapies for bladder cancer, glioblastoma, HIV, and other conditionsPartnerships and global expansion initiatives
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to NANTCELL, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.